Literature DB >> 10862840

Severe preeclampsia and high frequency of genetic thrombophilic mutations.

M J Kupferminc1, G Fait, A Many, D Gordon, A Eldor, J B Lessing.   

Abstract

OBJECTIVE: To determine whether severe preeclampsia is associated with genetic thrombophilic mutations or other types of thrombophilia.
METHODS: A case-control study compared 63 consecutive women with severe preeclampsia evaluated at our institution between November 1997 and April 1999 with 126 control women matched for age and ethnicity. All of these women were tested several months after delivery for mutations of factor V Leiden, methylenetetrahydrofolate reductase, and prothrombin gene; for deficiencies of protein C, protein S, and antithrombin-III; and for the presence of anticardiolipin antibodies.
RESULTS: Thirty-five study women (56%) had a thrombophilic mutation compared with 24 control women (19%), P <.001. Seven other study women (11%) had other thrombophilias, compared with one control woman (0.8%), P <.01. Within the study group, women with thrombophilia delivered at an earlier gestational age, and their neonates' birth weights were lower compared with those of women without thrombophilia.
CONCLUSION: Because thrombophilia was found in 67% of women with severe preeclampsia, we suggest that women who have severe preeclampsia should be tested for thrombophilia.

Entities:  

Mesh:

Year:  2000        PMID: 10862840     DOI: 10.1016/s0029-7844(00)00861-9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  17 in total

1.  The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.

Authors:  Cande V Ananth; Carl A Nath; Claire Philipp
Journal:  J Matern Fetal Neonatal Med       Date:  2010-03-24

2.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

3.  Folate metabolism gene polymorphisms MTHFR C677T and A1298C and risk for preeclampsia: a meta-analysis.

Authors:  Xiaoming Wu; Kunxian Yang; Xiaodan Tang; Yalian Sa; Ruoyu Zhou; Jing Liu; Ying Luo; Wenru Tang
Journal:  J Assist Reprod Genet       Date:  2015-03-11       Impact factor: 3.412

4.  Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study.

Authors:  K J Gibbins; A E Tebo; S K Nielsen; D W Branch
Journal:  Lupus       Date:  2018-07-20       Impact factor: 2.911

Review 5.  Thrombophilia and its treatment in pregnancy.

Authors:  A Eldor
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

6.  Methylenetetrahydrofolate Reductase C677T Polymorphism and Recurrent Pregnancy Loss Risk in Asian Population: A Meta-analysis.

Authors:  Vandana Rai
Journal:  Indian J Clin Biochem       Date:  2016-02-06

Review 7.  Congenital thrombophilia associated to obstetric complications.

Authors:  Cynthia Villarreal; Gerardo García-Aguirre; Carmen Hernández; Olynka Vega; José R Borbolla; María T Collados
Journal:  J Thromb Thrombolysis       Date:  2002-10       Impact factor: 2.300

Review 8.  Preeclampsia and the future risk of hypertension: the pregnant evidence.

Authors:  Vesna D Garovic; Phyllis August
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

Review 9.  Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test?

Authors:  Iasmina Craici; Steven Wagner; Vesna D Garovic
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-08

Review 10.  Preeclampsia and ABO blood groups: a systematic review and meta-analysis.

Authors:  Patricia Nessralla Alpoim; Melina de Barros Pinheiro; Daniela Rezende Garcia Junqueira; Leticia Gonçalves Freitas; Maria das Graças Carvalho; Ana Paula Salles Moura Fernandes; Flávia Komatsuzaki; Karina Braga Gomes; Luci Maria Sant'Ana Dusse
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.